Lukang Pharmaceutical subsidiary Montmorillonite scattered reviews
Release date: 2020-01-14 Views: 0
Recently, Lukang Pharmaceutical subsidiary Sete received the “Approval for Supplementary Drug Application” for Montmorillonite issued by the State Drug Administration (approval number: 2020B02000). Montmorillonite passed the consistency evaluation of the quality and efficacy of generic drugs .
It is reported that montmorillonite powder is the recommended medication for clinical guidelines for infectious diarrhea in China. At present, montmorillonite powder is mainly used for the adjuvant treatment of acute and chronic diarrhea, esophagus, stomach and duodenal disease related pain symptoms in adults and children.
The market prospect of montmorillonite is broad. From January to September 2019, the sales of the drug in domestic medical institution terminals and retail terminals were about 700 million yuan, and the sales revenue of this product by Scitech was 2.173 million yuan.
It is worth mentioning that there are currently 39 production approvals for montmorillonite in China. As of the date of this announcement, a total of 13 companies including Sichuan Weiao Pharmaceutical Co., Ltd., Yangzijiang Pharmaceutical Group Co., Ltd., and Shandong Lukang Pharmaceutical Group Sete Co., Ltd. have passed the consistent evaluation and approval of the State Drug Administration.
Source: Listed company announcement
- Basic introduction of Heilongjiang Hexiang Pharmaceutical Co., Ltd.
- How to contact Bermuda Medical (Shanghai) Regenerative Medicine Technology Co., Ltd.
- Shandong Dongfang Huiyi Health Industry Co., Ltd.
- Brief introduction of Zaozhuang Yinhai Pharmaceutical Co., Ltd.
- Contact information of Shandong Dongfang Huiyi Health Industry Co., Ltd.
- Introduction of Bermoudi (Shanghai) Regenerative Medicine Technology Co., Ltd.
- Nature子刊：2020年FDA可能批准的新药 1. Nature issue: FDA may approve new drugs in 2020
- “即用型”CAR-T疗法：权宜之计还是未来的发展方向？ 2. "Ready-to-use" CAR-T therapy: an expedient or future direction?
- 2019年全球新上市的重磅创新药盘点 3. Inventory of blockbuster innovative medicines listed globally in 2019
- 2019年12月全球批准新药概况 4. Global Approval of New Drugs in December 2019
- 18种！ 5. 18 types! National Health Commission issued the first batch of key national high-value medical consumables governance list
- 国家药监局发文为亚硝胺类杂质的控制提供指导 6.SFDA issued a document to provide guidance for the control of nitrosamine impurities
- 福建针对未过一致性评价药品开展带量采购 7.Fujian carries out volume procurement for drugs that have not been consistently evaluated